Literature DB >> 11857748

Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain.

Gemma Llort1, Carmen Yagüe Muñoz, Mercè Peris Tuser, Ignacio Blanco Guillermo, José Ramón Germà Lluch, Allen E Bale, Mayra Alvarez Franco.   

Abstract

BRCA1 and BRCA2 mutations underlie a substantial proportion of all hereditary breast cancer. The mutational spectrum in these genes is very broad, with hundreds of different BRCA mutations reported worldwide. However, high frequency founder mutations make up a substantial fraction of all mutations in some ethnic groups. We directly sequenced BRCA1 and BRCA2 in 35 Spanish breast/ovarian cancer families and found 13 mutations of which 3 had been reported previously in Spain. The ten novel mutations are: IVS5+1 G>A, 1491delA, Leu1086Ter, and Gln895Ter in BRCA1; Glu49Ter, 5373delGTAT, 5947delCTCT, 6672delTA, 8281insA, and Pro3039Leu (which also involves a splice site) in BRCA2. Our data, in combination with previous reports, indicate that 14 mutations have been seen recurrently in Spanish families. Analyzing these 14 mutations in 42 previously untested breast/ovarian cancer families revealed only two families testing positive, one for BRCA1 185delAG and one for BRCA2 9254delATCAT. While several mutations have been found recurrently in Spain, none appear to be high frequency founder mutations based on studies of breast and ovarian cancer families. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 11857748     DOI: 10.1002/humu.9014

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  12 in total

1.  BRCA1 variants in a family study of African-American and Latina women.

Authors:  Roberta McKean-Cowdin; Heather Spencer Feigelson; Lucy Y Xia; Celeste Leigh Pearce; Duncan C Thomas; Daniel O Stram; Brian E Henderson
Journal:  Hum Genet       Date:  2005-02-23       Impact factor: 4.132

2.  Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area: implications for genetic testing.

Authors:  Orland Diez; Sara Gutiérrez-Enríquez; Judith Balmaña
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

3.  Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.

Authors:  Elisabeth Jarhelle; Hilde Monica Frostad Riise Stensland; Lovise Mæhle; Marijke Van Ghelue
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

4.  Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.

Authors:  Jeffrey N Weitzel; Jessica Clague; Arelis Martir-Negron; Raquel Ogaz; Josef Herzog; Charité Ricker; Chelsy Jungbluth; Cheryl Cina; Paul Duncan; Gary Unzeitig; J Salvador Saldivar; Mary Beattie; Nancy Feldman; Sharon Sand; Danielle Port; Deborah I Barragan; Esther M John; Susan L Neuhausen; Garrett P Larson
Journal:  J Clin Oncol       Date:  2012-12-10       Impact factor: 44.544

5.  Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.

Authors:  Xavier Gabaldó Barrios; Mª Desamparados Sarabia Meseguer; Miguel Marín Vera; Ana Isabel Sánchez Bermúdez; José Antonio Macías Cerrolaza; Pilar Sánchez Henarejos; Marta Zafra Poves; Mª Rosario García Hernández; Encarna Cuevas Tortosa; Ángeles Aliaga Baño; Verónica Castillo Guardiola; Pedro Martínez Hernández; Isabel Tovar Zapata; Enrique Martínez Barba; Francisco Ayala de la Peña; José Luis Alonso Romero; José Antonio Noguera Velasco; Francisco Ruiz Espejo
Journal:  Fam Cancer       Date:  2017-10       Impact factor: 2.375

6.  BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.

Authors:  Inmaculada de Juan; Sarai Palanca; Asunción Domenech; Lidia Feliubadaló; Ángel Segura; Ana Osorio; Isabel Chirivella; Miguel de la Hoya; Ana Beatriz Sánchez; Mar Infante; Isabel Tena; Orland Díez; Zaida Garcia-Casado; Ana Vega; Àlex Teulé; Alicia Barroso; Pedro Pérez; Mercedes Durán; Estela Carrasco; M José Juan-Fita; Rosa Murria; Marta Llop; Eva Barragan; Ángel Izquierdo; Javier Benítez; Trinidad Caldés; Dolores Salas; Pascual Bolufer
Journal:  Fam Cancer       Date:  2015-12       Impact factor: 2.375

Review 7.  Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

Authors:  Murray Joseph Casey; Chhanda Bewtra
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

8.  Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence.

Authors:  Inmaculada de Juan Jiménez; Zaida García Casado; Sarai Palanca Suela; Eva Esteban Cardeñosa; José Antonio López Guerrero; Ángel Segura Huerta; Isabel Chirivella González; Ana Beatriz Sánchez Heras; Ma José Juan Fita; Isabel Tena García; Carmen Guillen Ponce; Eduardo Martínez de Dueñas; Ignacio Romero Noguera; Dolores Salas Trejo; Mercedes Goicoechea Sáez; Pascual Bolufer Gilabert
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

9.  Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome.

Authors:  Ingrid P Ewald; Patrícia Izetti; Fernando R Vargas; Miguel Am Moreira; Aline S Moreira; Carlos A Moreira-Filho; Danielle R Cunha; Sara Hamaguchi; Suzi A Camey; Aishameriane Schmidt; Maira Caleffi; Patrícia Koehler-Santos; Roberto Giugliani; Patricia Ashton-Prolla
Journal:  Hered Cancer Clin Pract       Date:  2011-12-20       Impact factor: 2.857

10.  Family history and breast cancer hormone receptor status in a Spanish cohort.

Authors:  Xuejuan Jiang; Jose Esteban Castelao; Elisabet Chavez-Uribe; Beatriz Fernandez Rodriguez; Catuxa Celeiro Muñoz; Carmen M Redondo; Maite Peña Fernandez; Alejandro Novo Dominguez; Carina Doris Pereira; María Elena Martínez; Tomás García-Caballero; Máximo Fraga Rodriguez; José Antúnez; Angel Carracedo; Jerónimo Forteza-Vila; Manuela Gago-Dominguez
Journal:  PLoS One       Date:  2012-01-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.